An Electronic Aerosol Delivery System for Functional Magnetic Resonance Imaging.
Electronic cigarette
addiction
aerosol
magnetic resonance imaging
nicotine
vaping
Journal
Substance abuse : research and treatment
ISSN: 1178-2218
Titre abrégé: Subst Abuse
Pays: United States
ID NLM: 101514834
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
12
2019
accepted:
10
01
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
26
2
2020
Statut:
epublish
Résumé
Public health concerns over the addictive potential of electronic cigarettes (e-cigs) have heightened in recent years. Brain function during e-cig use could provide an objective measure of the addictive potential of new vaping products to facilitate research; however, there are limited methods for delivering e-cig aerosols during functional magnetic resonance imaging (fMRI). The current study describes the development and feasibility testing of a prototype to deliver up to four different e-cig aerosols during fMRI. Standardized methods were used to test the devices' air flow variability, nicotine yield, and free radical production. MRI scans were run with and without the device present to assess its safety and effects on MRI data quality. Five daily smokers were recruited to assess plasma nicotine absorption from e-liquids containing nicotine concentrations of 8, 11, 16, 24, and 36 mg/ml. Feedback was collected from participants through a semi-structured interview and computerized questionnaire to assess comfort and subjective experiences of inhaling aerosol from the device. Nicotine yield captured from the aerosol produced by the device was highly correlated with the nicotine concentration of the e-liquids used (R With the current project, we were able to design a working prototype that safely and effectively delivers e-cig aerosols during fMRI. The device has the potential to be used to assess brain activation during e-cig use and to compare brain reactivity to varying flavors, nicotine concentrations, and other e-cig characteristics.
Sections du résumé
BACKGROUND
BACKGROUND
Public health concerns over the addictive potential of electronic cigarettes (e-cigs) have heightened in recent years. Brain function during e-cig use could provide an objective measure of the addictive potential of new vaping products to facilitate research; however, there are limited methods for delivering e-cig aerosols during functional magnetic resonance imaging (fMRI). The current study describes the development and feasibility testing of a prototype to deliver up to four different e-cig aerosols during fMRI.
METHODS
METHODS
Standardized methods were used to test the devices' air flow variability, nicotine yield, and free radical production. MRI scans were run with and without the device present to assess its safety and effects on MRI data quality. Five daily smokers were recruited to assess plasma nicotine absorption from e-liquids containing nicotine concentrations of 8, 11, 16, 24, and 36 mg/ml. Feedback was collected from participants through a semi-structured interview and computerized questionnaire to assess comfort and subjective experiences of inhaling aerosol from the device.
RESULTS
RESULTS
Nicotine yield captured from the aerosol produced by the device was highly correlated with the nicotine concentration of the e-liquids used (R
CONCLUSIONS
CONCLUSIONS
With the current project, we were able to design a working prototype that safely and effectively delivers e-cig aerosols during fMRI. The device has the potential to be used to assess brain activation during e-cig use and to compare brain reactivity to varying flavors, nicotine concentrations, and other e-cig characteristics.
Identifiants
pubmed: 32095075
doi: 10.1177/1178221820904140
pii: 10.1177_1178221820904140
pmc: PMC7013112
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178221820904140Subventions
Organisme : NIDA NIH HHS
ID : K23 DA045081
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000127
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interest:The authors declare that there is no conflict of interest.
Références
Magn Reson Med. 2010 Aug;64(2):439-46
pubmed: 20665788
JAMA Netw Open. 2019 Nov 1;2(11):e1915494
pubmed: 31730180
Sci Rep. 2017 Sep 12;7(1):11352
pubmed: 28900267
Drug Alcohol Depend. 2015 Feb 1;147:68-75
pubmed: 25561385
J Vis Exp. 2012 Jan 02;(59):e3406
pubmed: 22230844
Prev Med. 2017 Nov;104:86-91
pubmed: 28389330
Free Radic Biol Med. 2018 May 20;120:72-79
pubmed: 29548792
Nicotine Tob Res. 2018 Oct 27;:
pubmed: 30371838
Nicotine Tob Res. 2019 Aug 22;:
pubmed: 31437266
Curr Drug Abuse Rev. 2008 Jan;1(1):9-19
pubmed: 19630701
Nicotine Tob Res. 2015 Feb;17(2):186-92
pubmed: 25332459
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
J Clin Invest. 2003 May;111(10):1444-51
pubmed: 12750391
Nicotine Tob Res. 2019 Jun 29;:
pubmed: 31254382
PLoS One. 2019 Jul 25;14(7):e0220300
pubmed: 31344110
Tob Control. 2019 Sep;28(5):493-497
pubmed: 30097510
Trends Mol Med. 2006 Dec;12(12):559-66
pubmed: 17070107
Nicotine Tob Res. 2019 Aug 19;21(9):1274-1278
pubmed: 30346584
Chem Res Toxicol. 2015 Sep 21;28(9):1675-7
pubmed: 26244921
Eur Neuropsychopharmacol. 2018 Oct;28(10):1089-1102
pubmed: 30093174
Curr Opin Pharmacol. 2007 Feb;7(1):69-76
pubmed: 17174602
Am J Prev Med. 2017 Aug;53(2):139-151
pubmed: 28318902
Magn Reson Med. 2005 Dec;54(6):1439-47
pubmed: 16261576
Saudi Pharm J. 2018 Jul;26(5):622-628
pubmed: 29989025
Chem Res Toxicol. 2018 Jan 16;31(1):4-12
pubmed: 29161504